Notably, the interaction between TRPV1 and CB1 receptors is crucial for the pharmacodynamics of cannabidiol, which is currently used in children with pharmacoresistant epilepsy, such as Dravet or Lennox–Gastaut syndromes [69, 71, 72]. Here, TRPV1 is linked to epilepsy.